Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

被引:7
|
作者
Rosen, Jeffrey B. [1 ]
Ballantyne, Christie M. [2 ,3 ]
Hsueh, Willa A. [4 ]
Lin, Jianxin [5 ]
Shah, Arvind K. [5 ]
Lowe, Robert S. [5 ]
Tershakovec, Andrew M. [5 ]
机构
[1] Clin Res South Florida, Coral Gables, FL 33134 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA
[4] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[5] Merck & Co Inc, Kenilworth, NJ USA
来源
LIPIDS IN HEALTH AND DISEASE | 2015年 / 14卷
关键词
TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR RISK; HYPERCHOLESTEROLEMIA; EZETIMIBE; DYSLIPIDEMIA; COMBINATION; MANAGEMENT; SIMVASTATIN; PREVENTION; SUBCLASSES;
D O I
10.1186/s12944-015-0075-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated with higher risk for coronary heart disease (CHD), and may potentially influence the responses to lipid-altering drug therapy. This study evaluated the effects of MetS factors (abdominal obesity, depleted high-density lipoprotein cholesterol [HDL-C], and elevated triglycerides, blood pressure, and fasting glucose) and IR on ezetimibe/simvastatin and atorvastatin treatment efficacy in patients with MetS. Methods: This post-hoc analysis of a multicenter, 6-week, double-blind, randomized, parallel group study of 1128 subjects with hypercholesterolemia, MetS, and moderately high/high CHD risk evaluated the effects of baseline MetS factors/IR on percent change from baseline in lipids, apolipoproteins, and high-sensitivity C-reactive protein (hs-CRP), after treatment with the usual starting doses of ezetimibe/simvastatin (10/20 mg) versus atorvastatin (10 mg, 20 mg) and next higher doses (10/40 mg versus 40 mg). Results: Ezetimibe/simvastatin and atorvastatin efficacy was generally consistent across MetS factor/IR subgroups. Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C >= 40 mg/dL subgroups than atorvastatin at the doses compared. Triglycerides, very-LDL-C, and hs-CRP results were more variable but similar between treatment groups. Conclusion: The magnitude of lipid-altering effects produced by each treatment regimen was generally similar across all MetS and IR subgroups. Ezetimibe/simvastatin produced greater percent reductions in most lipid fractions than atorvastatin at the dose comparisons studied, and all treatments were generally well tolerated.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk
    Jeffrey B. Rosen
    Christie M. Ballantyne
    Willa A. Hsueh
    Jianxin Lin
    Arvind K. Shah
    Robert S. Lowe
    Andrew M. Tershakovec
    Lipids in Health and Disease, 14
  • [2] Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither
    Conard, S.
    Bays, H.
    Leiter, L. A.
    Bird, S.
    Lin, J.
    Hanson, M. E.
    Shah, A.
    Tershakovec, A. M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (03) : 210 - 218
  • [3] Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Hypercholesterolemia and the Metabolic Syndrome (from the VYMET Study)
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Grundy, Scott M.
    Hsueh, Willa A.
    Parving, Hans-Henrik
    Rosen, Jeffrey B.
    Adewale, Adeniyi J.
    Polis, Adam B.
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (12) : 1694 - 1702
  • [4] Ezetimibe/Simvastatin or Atorvastatin for the Treatment of Hypercholesterolemia in Patients with the Metabolic Syndrome: The VYMET Study
    Jennifer Villa
    Richard E. Pratley
    Current Diabetes Reports, 2010, 10 (3) : 173 - 175
  • [5] Relationships Between Metabolic Syndrome and Other Baseline Factors and the Efficacy of Ezetimibe/Simvastatin and Atorvastatin in Patients With Type 2 Diabetes and Hypercholesterolemia
    Goldberg, Ronald B.
    Guyton, John R.
    Mazzone, Theodore
    Weinstock, Ruth S.
    Polis, Adam B.
    Tipping, Diane
    Tomassini, Joanne E.
    Tershakovec, Andrew M.
    DIABETES CARE, 2010, 33 (05) : 1021 - 1024
  • [6] Ezetimibe combined with standard diet and exercise therapy improves insulin resistance and atherosclerotic markers in patients with metabolic syndrome
    Ohbu-Murayama, Kyoko
    Adachi, Hisashi
    Hirai, Yuji
    Enomoto, Mika
    Fukami, Ako
    Obuchi, Aya
    Yoshimura, Ayako
    Nakamura, Sachiko
    Nohara, Yume
    Nakao, Erika
    Umeki, Yoko
    Fukumoto, Yoshihiro
    Journal of Diabetes Investigation, 2015, 6 (03) : 325 - 333
  • [7] The Effects of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Platelet and Inflammatory Biomarkers in Patients with Metabolic Syndrome
    Miller, Michael
    DiNicolantonio, James J.
    Can, Mehmet
    Grice, Rachel
    Damoulakis, Abigail
    Serebruany, Victor L.
    CARDIOLOGY, 2013, 125 (02) : 74 - 77
  • [8] Prevalence of Coronary Artery Disease Risk Factors and Metabolic Syndrome in Children with Heart Disease
    Adam L. Ware
    Paul C. Young
    Cindy Weng
    Angela P. Presson
    L. LuAnn Minich
    Shaji C. Menon
    Pediatric Cardiology, 2018, 39 : 261 - 267
  • [9] Prevalence of Coronary Artery Disease Risk Factors and Metabolic Syndrome in Children with Heart Disease
    Ware, Adam L.
    Young, Paul C.
    Weng, Cindy
    Presson, Angela P.
    Minich, L. LuAnn
    Menon, Shaji C.
    PEDIATRIC CARDIOLOGY, 2018, 39 (02) : 261 - 267
  • [10] Metabolic syndrome and coronary heart disease
    Gurgenyan, S. V.
    Vatinyan, S. Kh
    Zelveian, P. A.
    TERAPEVTICHESKII ARKHIV, 2014, 86 (03) : 106 - 110